|
1
|
Nathanson L and Hall TC: Introduction:
paraneoplastic syndromes. Semin Oncol. 24:265–268. 1997.PubMed/NCBI
|
|
2
|
Nakamura I, Shibata M, Gonda K, et al:
Serum levels of vascular endothelial growth factor are increased
and correlate with malnutrition, immunosuppression involving MDSCs
and systemic inflammation in patients with cancer of the digestive
system. Oncol Lett. 5:1682–1686. 2013.PubMed/NCBI
|
|
3
|
Tisdale MJ: Cachexia in cancer patients.
Nat Rev Cancer. 2:862–871. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Inui A: Cancer anorexia-cachexia syndrome:
current issues in research and management. CA Cancer J Clin.
52:72–91. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Takahashi Y, Yasumoto K and Mai M:
Chemotherapy under cachectic conditions and the possibility of
cachexia-controlled chemotherapy. Oncol Rep. 14:135–140.
2005.PubMed/NCBI
|
|
6
|
Krzystek-Korpacka M, Matusiewicz M,
Diakowska D, et al: Impact of weight loss on circulating IL-1,
IL-6, IL-8, TNF-alpha, VEGF-A, VEGF-C and midkine in
gastroesophageal cancer patients. Clin Biochem. 40:1353–1360. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ebos JM, Lee CR, Christensen JG, et al:
Multiple circulating proangiogenic factors induced by sunitinib
malate are tumor-independent and correlate with antitumor efficacy.
Proc Natl Acad Sci USA. 104:17069–17074. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xue Y, Religa P, Cao R, et al: Anti-VEGF
agents confer survival advantages to tumor-bearing mice by
improving cancer-associated systemic syndrome. Proc Natl Acad Sci
USA. 105:18513–18518. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cao Y: Off-tumor target - beneficial site
for antiangiogenic cancer therapy? Nat Rev Clin Oncol. 7:604–608.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ling Y, Yang Y, Lu N, et al: Endostar, a
novel recombinant human endostatin, exerts antiangiogenic effect
via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of
endothelial cells. Biochem Biophys Res Commun. 361:79–84. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang Y, Zhang J, Jiang D, et al:
Inhibition of T-type Ca2+ channels by endostatin
attenuates human glioblastoma cell proliferation and migration. Br
J Pharmacol. 166:1247–1260. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lim J, Duong T, Lee G, et al: The effect
of intracellular protein delivery on the anti-tumor activity of
recombinant human endostatin. Biomaterials. 34:6261–6271. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xu W, Ye P, Li Z, et al: Endostar, a
recently introduced recombinant human endostatin, inhibits
proliferation and migration through regulating growth factors,
adhesion factors and inflammatory mediators in choroid-retinal
endothelial cells. Mol Biol (Mosk). 44:664–670. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huszthy PC, Brekken C, Pedersen TB, et al:
Antitumor efficacy improved by local delivery of species-specific
endostatin. J Neurosurg. 104:118–128. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang X, Yang G, Zhang Y, et al: An
experimental research into endostatin microbubble combined with
focused ultrasound for anti-tumor angiogenesis in colon cancer.
Gastroenterol Rep (Oxf). 2:44–53. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ning T, Jiang M, Peng Q, et al: Low-dose
endostatin normalizes the structure and function of tumor
vasculature and improves the delivery and anti-tumor efficacy of
cytotoxic drugs in a lung cancer xenograft murine model. Thoracic
Cancer. 3:229–238. 2012. View Article : Google Scholar
|
|
17
|
Jain RK: Normalization of tumor
vasculature: an emerging concept in antiangiogenic therapy.
Science. 307:58–62. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kayacan O, Karnak D, Beder S, et al:
Impact of TNF-alpha and IL-6 levels on development of cachexia in
newly diagnosed NSCLC patients. Am J Clin Oncol. 29:328–335. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang Q, Wan L, Zhou Z, et al: Parthenolide
from Parthenium integrifolium reduces tumor burden and alleviate
cachexia symptoms in the murine CT-26 model of colorectal
carcinoma. Phytomedicine. 20:992–998. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Noguchi Y, Makino T, Yoshikawa T, et al:
The possible role of TNF-alpha and IL-2 in inducing
tumor-associated metabolic alterations. Surg Today. 26:36–41. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Barton BE and Murphy TF: Cancer cachexia
is mediated in part by the induction of IL-6-like cytokines from
the spleen. Cytokine. 16:251–257. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu S, Wu HJ, Zhang ZQ, et al: L-carnitine
ameliorates cancer cachexia in mice by regulating the expression
and activity of carnitine palmityl transferase. Cancer Biol Ther.
12:125–130. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kamba T, Tam BY, Hashizume H, et al:
VEGF-dependent plasticity of fenestrated capillaries in the normal
adult microvasculature. Am J Physiol Heart Circ Physiol.
290:H560–H576. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rein DT, Volkmer AK, Volkmer J, et al:
Systemic administration of bevacizumab prolongs survival in an in
vivo model of platinum pre-treated ovarian cancer. Oncol Lett.
3:530–534. 2012.PubMed/NCBI
|
